Do analysts recommend RGC or ONC?

BeOne Medicines has a consensus target price of $390.00, suggesting a potential upside of 39.34%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts plainly believe BeOne Medicines is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BeOne Medicines 1 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 2.93

Which has better earnings and valuation, RGC or ONC?

BeOne Medicines has higher revenue and earnings than Regencell Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A BeOne Medicines $5.34B 5.75 $286.93M $4.47 62.62

Does the media refer more to RGC or ONC?

In the previous week, Regencell Bioscience had 2 more articles in the media than BeOne Medicines. MarketBeat recorded 16 mentions for Regencell Bioscience and 14 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.14 beat Regencell Bioscience's score of 0.07 indicating that BeOne Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral BeOne Medicines 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer BNTX or RGC?

BioNTech presently has a consensus target price of $129.56, indicating a potential upside of 42.03%. Given BioNTech's stronger consensus rating and higher probable upside, equities analysts plainly believe BioNTech is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNTech 1 Sell rating(s) 4 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.74 Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, BNTX or RGC?

Regencell Bioscience has lower revenue, but higher earnings than BioNTech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioNTech $2.81B 8.22 -$1.29B -$5.88 N/A Regencell Bioscience N/A N/A -$3.58M N/A N/A

Does the media refer more to BNTX or RGC?

In the previous week, Regencell Bioscience had 13 more articles in the media than BioNTech. MarketBeat recorded 16 mentions for Regencell Bioscience and 3 mentions for BioNTech. BioNTech's average media sentiment score of 1.31 beat Regencell Bioscience's score of 0.07 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regencell Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts rate RGC or MRNA?

Moderna has a consensus target price of $37.13, suggesting a potential downside of 44.80%. Given Moderna's stronger consensus rating and higher probable upside, analysts clearly believe Moderna is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Moderna 5 Sell rating(s) 11 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.83

Which has higher valuation & earnings, RGC or MRNA?

Regencell Bioscience has higher earnings, but lower revenue than Moderna. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Moderna $1.94B 13.73 -$2.82B -$8.15 N/A

Does the media prefer RGC or MRNA?

In the previous week, Moderna had 8 more articles in the media than Regencell Bioscience. MarketBeat recorded 24 mentions for Moderna and 16 mentions for Regencell Bioscience. Moderna's average media sentiment score of 0.52 beat Regencell Bioscience's score of 0.07 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Moderna 10 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ROIV or RGC?

Roivant Sciences currently has a consensus target price of $33.59, indicating a potential downside of 1.41%. Given Roivant Sciences' stronger consensus rating and higher possible upside, research analysts plainly believe Roivant Sciences is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Roivant Sciences 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.75 Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, ROIV or RGC?

Regencell Bioscience has lower revenue, but higher earnings than Roivant Sciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Roivant Sciences $8.26M 2,966.77 -$299.77M -$0.60 N/A Regencell Bioscience N/A N/A -$3.58M N/A N/A

Does the media refer more to ROIV or RGC?

In the previous week, Regencell Bioscience had 8 more articles in the media than Roivant Sciences. MarketBeat recorded 16 mentions for Regencell Bioscience and 8 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.49 beat Regencell Bioscience's score of 0.07 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regencell Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend INSM or RGC?

Insmed presently has a consensus target price of $211.86, suggesting a potential upside of 104.94%. Given Insmed's stronger consensus rating and higher probable upside, research analysts plainly believe Insmed is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Insmed 1 Sell rating(s) 0 Hold rating(s) 23 Buy rating(s) 1 Strong Buy rating(s) 2.96 Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, INSM or RGC?

Regencell Bioscience has lower revenue, but higher earnings than Insmed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 36.95 -$1.28B -$5.75 N/A Regencell Bioscience N/A N/A -$3.58M N/A N/A

Does the media favor INSM or RGC?

In the previous week, Regencell Bioscience had 1 more articles in the media than Insmed. MarketBeat recorded 16 mentions for Regencell Bioscience and 15 mentions for Insmed. Insmed's average media sentiment score of 1.07 beat Regencell Bioscience's score of 0.07 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 9 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regencell Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Regencell Bioscience (RGC) Competitors

$6.48 -1.01 (-13.48%)

Closing price 04:00 PM Eastern

Extended Trading

$6.38 -0.10 (-1.48%)

As of 07:56 PM Eastern

Compare

RGC vs. ONC, BNTX, MRNA, ROIV, and INSM

Should you buy Regencell Bioscience stock or one of its competitors? MarketBeat compares Regencell Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Regencell Bioscience include BeOne Medicines (ONC), BioNTech (BNTX), Moderna (MRNA), Roivant Sciences (ROIV), and Insmed (INSM). These companies are all part of the "pharmaceutical products" industry.

How does Regencell Bioscience compare to BeOne Medicines?

Regencell Bioscience (NASDAQ:RGC) and BeOne Medicines (NASDAQ:ONC) are both pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by company insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

BeOne Medicines has a consensus target price of $390.00, suggesting a potential upside of 39.34%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts plainly believe BeOne Medicines is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

In the previous week, Regencell Bioscience had 2 more articles in the media than BeOne Medicines. MarketBeat recorded 16 mentions for Regencell Bioscience and 14 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.14 beat Regencell Bioscience's score of 0.07 indicating that BeOne Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
BeOne Medicines	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

BeOne Medicines has higher revenue and earnings than Regencell Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
BeOne Medicines	$5.34B	5.75	$286.93M	$4.47	62.62

Regencell Bioscience has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market.

BeOne Medicines has a net margin of 8.94% compared to Regencell Bioscience's net margin of 0.00%. BeOne Medicines' return on equity of 12.06% beat Regencell Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
BeOne Medicines	8.94%	12.06%	6.69%

Summary

BeOne Medicines beats Regencell Bioscience on 12 of the 14 factors compared between the two stocks.

How does Regencell Bioscience compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Regencell Bioscience (NASDAQ:RGC) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

BioNTech has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market.

Regencell Bioscience has lower revenue, but higher earnings than BioNTech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.81B	8.22	-$1.29B	-$5.88	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 2.0% of Regencell Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Regencell Bioscience has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. Regencell Bioscience's return on equity of 0.00% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Regencell Bioscience	N/A	N/A	N/A

BioNTech presently has a consensus target price of $129.56, indicating a potential upside of 42.03%. Given BioNTech's stronger consensus rating and higher probable upside, equities analysts plainly believe BioNTech is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Regencell Bioscience had 13 more articles in the media than BioNTech. MarketBeat recorded 16 mentions for Regencell Bioscience and 3 mentions for BioNTech. BioNTech's average media sentiment score of 1.31 beat Regencell Bioscience's score of 0.07 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regencell Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

BioNTech beats Regencell Bioscience on 8 of the 14 factors compared between the two stocks.

How does Regencell Bioscience compare to Moderna?

Regencell Bioscience (NASDAQ:RGC) and Moderna (NASDAQ:MRNA) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

Regencell Bioscience has higher earnings, but lower revenue than Moderna.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Moderna	$1.94B	13.73	-$2.82B	-$8.15	N/A

Moderna has a consensus target price of $37.13, suggesting a potential downside of 44.80%. Given Moderna's stronger consensus rating and higher probable upside, analysts clearly believe Moderna is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Moderna had 8 more articles in the media than Regencell Bioscience. MarketBeat recorded 24 mentions for Moderna and 16 mentions for Regencell Bioscience. Moderna's average media sentiment score of 0.52 beat Regencell Bioscience's score of 0.07 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Moderna	10 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Regencell Bioscience has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market. Comparatively, Moderna has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

Regencell Bioscience has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Regencell Bioscience's return on equity of 0.00% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Moderna	-143.55%	-26.64%	-19.32%

Summary

Moderna beats Regencell Bioscience on 8 of the 13 factors compared between the two stocks.

How does Regencell Bioscience compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Regencell Bioscience (NASDAQ:RGC) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Regencell Bioscience has lower revenue, but higher earnings than Roivant Sciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,966.77	-$299.77M	-$0.60	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

Roivant Sciences currently has a consensus target price of $33.59, indicating a potential downside of 1.41%. Given Roivant Sciences' stronger consensus rating and higher possible upside, research analysts plainly believe Roivant Sciences is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Regencell Bioscience had 8 more articles in the media than Roivant Sciences. MarketBeat recorded 16 mentions for Regencell Bioscience and 8 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.49 beat Regencell Bioscience's score of 0.07 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regencell Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by insiders. Comparatively, 2.0% of Regencell Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Roivant Sciences has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market.

Regencell Bioscience has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Regencell Bioscience's return on equity of 0.00% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Regencell Bioscience	N/A	N/A	N/A

Summary

Roivant Sciences beats Regencell Bioscience on 7 of the 13 factors compared between the two stocks.

How does Regencell Bioscience compare to Insmed?

Insmed (NASDAQ:INSM) and Regencell Bioscience (NASDAQ:RGC) are both pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

Regencell Bioscience has lower revenue, but higher earnings than Insmed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	36.95	-$1.28B	-$5.75	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

In the previous week, Regencell Bioscience had 1 more articles in the media than Insmed. MarketBeat recorded 16 mentions for Regencell Bioscience and 15 mentions for Insmed. Insmed's average media sentiment score of 1.07 beat Regencell Bioscience's score of 0.07 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	9 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regencell Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

0.1% of Regencell Bioscience shares are owned by institutional investors. 2.1% of Insmed shares are owned by company insiders. Comparatively, 2.0% of Regencell Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Insmed presently has a consensus target price of $211.86, suggesting a potential upside of 104.94%. Given Insmed's stronger consensus rating and higher probable upside, research analysts plainly believe Insmed is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Insmed has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market.

Regencell Bioscience has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Regencell Bioscience's return on equity of 0.00% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Regencell Bioscience	N/A	N/A	N/A

Summary

Insmed and Regencell Bioscience tied by winning 7 of the 14 factors compared between the two stocks.

Get Regencell Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RGC vs. The Competition

Export

Metric	Regencell Bioscience	Medicinal Chemicals Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$3.70B	$1.81B	$4.35B	$12.24B
Dividend Yield	N/A	N/A	12.96%	6.10%
P/E Ratio	N/A	N/A	21.95	24.18
Price / Sales	N/A	0.75	159.52	102.02
Price / Cash	N/A	0.27	38.27	54.37
Price / Book	648.00	324.03	13.62	6.35
Net Income	-$3.58M	-$1.41M	$115.37M	$337.63M
7 Day Performance	-46.04%	-27.90%	-1.12%	-0.30%
1 Month Performance	-73.34%	-73.34%	-2.51%	0.36%
1 Year Performance	-67.90%	-67.90%	10.88%	26.94%

Regencell Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RGC Regencell Bioscience	0.3022 of 5 stars	$6.48 -13.5%	N/A	-65.5%	$3.70B	N/A	N/A	10	Analyst Forecast Gap Down High Trading Volume
ONC BeOne Medicines	4.7752 of 5 stars	$262.68 -0.5%	$390.00 +48.5%	+3.1%	$28.96B	$5.34B	59.04	12,000	Insider Trade
BNTX BioNTech	4.2825 of 5 stars	$92.22 +3.0%	$129.56 +40.5%	-14.1%	$22.63B	$3.25B	N/A	7,807	Positive News
MRNA Moderna	0.978 of 5 stars	$61.80 +11.6%	$36.60 -40.8%	+122.4%	$21.98B	$1.94B	N/A	4,700	Trending News Analyst Forecast High Trading Volume
ROIV Roivant Sciences	2.1088 of 5 stars	$31.20 +2.6%	$33.59 +7.7%	+198.4%	$21.87B	$8.26M	N/A	860	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RGC) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Regencell Bioscience (RGC) Competitors

RGC vs. ONC, BNTX, MRNA, ROIV, and INSM

How does Regencell Bioscience compare to BeOne Medicines?

Summary

How does Regencell Bioscience compare to BioNTech?

Summary

How does Regencell Bioscience compare to Moderna?

Summary

How does Regencell Bioscience compare to Roivant Sciences?

Summary

How does Regencell Bioscience compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGC vs. The Competition

Regencell Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Regencell Bioscience (RGC) Competitors

RGC vs. ONC, BNTX, MRNA, ROIV, and INSM

How does Regencell Bioscience compare to BeOne Medicines?

Do institutionals & insiders hold more shares of RGC or ONC?

Do analysts recommend RGC or ONC?

Does the media refer more to RGC or ONC?

Which has better earnings and valuation, RGC or ONC?

Which has more risk and volatility, RGC or ONC?

Is RGC or ONC more profitable?

Summary

How does Regencell Bioscience compare to BioNTech?

Which has more volatility and risk, BNTX or RGC?

Which has preferable valuation and earnings, BNTX or RGC?

Do institutionals and insiders believe in BNTX or RGC?

Is BNTX or RGC more profitable?

Do analysts prefer BNTX or RGC?

Does the media refer more to BNTX or RGC?

Summary

How does Regencell Bioscience compare to Moderna?

Which has higher valuation & earnings, RGC or MRNA?

Do analysts rate RGC or MRNA?

Do institutionals & insiders hold more shares of RGC or MRNA?

Does the media prefer RGC or MRNA?

Which has more volatility and risk, RGC or MRNA?

Is RGC or MRNA more profitable?

Summary

How does Regencell Bioscience compare to Roivant Sciences?

Which has higher earnings & valuation, ROIV or RGC?

Do analysts recommend ROIV or RGC?

Does the media refer more to ROIV or RGC?

Do insiders and institutionals hold more shares of ROIV or RGC?

Which has more volatility & risk, ROIV or RGC?

Is ROIV or RGC more profitable?

Summary

How does Regencell Bioscience compare to Insmed?

Which has higher earnings and valuation, INSM or RGC?

Does the media favor INSM or RGC?

Do institutionals and insiders hold more shares of INSM or RGC?

Do analysts recommend INSM or RGC?

Which has more risk & volatility, INSM or RGC?

Is INSM or RGC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGC vs. The Competition

Regencell Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools